Nasal administration tube

Abstract

The nasal administration tube comprises a tube body and a medicine bag, a ventilation cavity is formed in the tube body, the tube body is provided with a first ventilation opening and a second ventilation opening which are communicated with the ventilation cavity, the medicine bag is arranged on the tube body in a sleeved mode, and the outer wall face of the tube body and the medicine bag are connected and form an administration cavity in a surrounding mode. A cotton piece is arranged in the medicine feeding cavity, and the medicine bag is provided with a plurality of medicine feeding holes communicated with the medicine feeding cavity. The utility model can solve the problems that in the existing nasal treatment, the medicine cannot be continuously administrated, the patient cannot use the nasal cavity to ventilate, and the discomfort of the patient is easily caused.

Description

Technical Field

[0001] This utility model belongs to the field of medical device technology, and specifically relates to a nasal drug delivery tube. Background Technology

[0002] Nasal administration is a novel method of drug delivery that uses the nasal cavity to treat systemic or local diseases. Because it bypasses the first-pass effect of the liver and the blood-brain barrier, it features rapid onset of action, high bioavailability, ease of use, and non-invasiveness.

[0003] Current nasal medication administration methods generally use spray bottles, but these cannot provide continuous administration and therefore cannot ensure sustained drug efficacy. Other methods involve soaking cotton gauze strips or cotton balls in various medications and then inserting them into the nasal cavity for continuous treatment. However, this prevents patients from using their nasal passages for ventilation, easily causing discomfort such as dry mouth and nasal congestion. Utility Model Content

[0004] The purpose of this invention is to provide a nasal drug delivery tube to solve the technical problems existing in current nasal treatments, such as the inability to continuously administer drugs, the inability of patients to use nasal ventilation, and the ease with which patients may experience discomfort.

[0005] The technical solution adopted to solve the above-mentioned technical problems is as follows:

[0006] This utility model discloses a nasal drug delivery tube, including a tube body and a drug capsule. The tube body has an internal ventilation cavity, and the tube body has a first ventilation port and a second ventilation port that communicate with the ventilation cavity. The drug capsule is sleeved on the tube body. The outer wall of the tube body and the drug capsule are connected and surround each other to form a drug delivery cavity. A cotton pad is placed inside the drug delivery cavity, and the drug capsule has multiple drug delivery holes that communicate with the drug delivery cavity.

[0007] The present invention has at least the following beneficial effects: When the tube is inserted into the patient's nasal cavity, the patient can breathe through the connected first airway, airway cavity, and second airway, avoiding the situation where the patient can only breathe through their mouth during nasal treatment, leading to dry mouth, changes in facial appearance, oral diseases, sleep disturbances, and snoring. A medication capsule is fitted onto the tube, and the outer walls of the capsule and tube form a medication delivery cavity. A cotton pad is placed inside the medication delivery cavity. When the tube is inserted into the patient's nasal cavity, the medication capsule is also inserted along with the tube. The medication-soaked cotton pad can continuously deliver medication into the nasal cavity through multiple delivery holes, achieving continuous nasal treatment.

[0008] As a further improvement to the above technical solution, the end of the tube with the second airway is inserted into the patient's inferior nasal meatus, while the end of the tube with the first airway is located outside the patient's nasal cavity.

[0009] As a further improvement to the above technical solution, the end of the tube with the first vent is connected to a drug injection port, and the drug injection port is connected to the drug delivery chamber.

[0010] As a further improvement to the above technical solution, the second vent is shaped like an eagle's beak.

[0011] As a further improvement to the above technical solution, the outer wall surface of the tube is provided with a scale, which is set along the long end of the tube.

[0012] As a further improvement to the above technical solution, the drug capsule is annular, the drug delivery chamber is annular, and the scale is located between the drug capsule and the first vent.

[0013] As a further improvement to the above technical solution, the drug capsule has a C-shaped structure, the drug delivery cavity has a C-shaped shape, and the scale is located between the two ends of the C-shaped drug capsule.

[0014] As a further improvement to the above technical solution, a fiberoptic bronchoscope used to observe the nasal mucosa passes through the first ventilation port, passes through the ventilation cavity, and extends out to the second ventilation port.

[0015] As a further improvement to the above technical solution, the sac is a plastic tube or film.

[0016] As a further improvement to the above technical solution, the diameter of the drug delivery hole is 0.25 mm, and the distance between two adjacent drug delivery holes is 2 mm;

[0017] And / or, the outer diameter of the tube is 6.8 mm, the length of the tube is 12 cm, and the length of the sac is 9 cm. Attached Figure Description

[0018] The present invention will be further described below with reference to the accompanying drawings and embodiments;

[0019] Figure 1 This is a schematic diagram of the structure of a nasal drug delivery tube provided in an embodiment of the present invention;

[0020] Figure 2 This is a cross-sectional view of a nasal delivery tube provided in an embodiment of the present invention;

[0021] Figure 3 This is a schematic diagram of another nasal delivery tube provided in an embodiment of the present invention.

[0022] The following labels are shown in the attached diagram:

[0023] 100. Nasal delivery tube;

[0024] 200. Pipe body; 210. First vent; 220. Second vent;

[0025] 300. Ventilation chamber;

[0026] 400. Drug capsule; 410. Drug delivery chamber; 420. Drug delivery port;

[0027] 500, cotton pads;

[0028] 600. Injection port;

[0029] 700, scale. Detailed Implementation

[0030] This section will describe in detail the specific embodiments of the present utility model. The preferred embodiments of the present utility model are shown in the accompanying drawings. The purpose of the drawings is to supplement the textual description with graphics, so that people can intuitively and vividly understand each technical feature and the overall technical solution of the present utility model, but they should not be construed as limiting the scope of protection of the present utility model.

[0031] In the description of this utility model, it should be understood that the directional descriptions, such as up, down, front, back, left, right, etc., indicate the directional or positional relationship based on the directional or positional relationship shown in the accompanying drawings. They are only for the convenience of describing this utility model and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, they should not be construed as limitations on this utility model.

[0032] In the description of this utility model, the use of terms such as "several" means one or more, with "multiple" meaning two or more. Terms like "greater than," "less than," and "exceeding" are understood to exclude the stated number, while "above," "below," and "within" are understood to include the stated number. The use of terms like "first," "second," and "third" is merely for distinguishing technical features and should not be construed as indicating or implying relative importance, the quantity of indicated technical features, or the sequential relationship between indicated technical features.

[0033] In the description of this utility model, unless otherwise explicitly defined, terms such as "setting," "installation," and "connection" should be interpreted broadly, and those skilled in the art can reasonably determine the specific meaning of the above terms in this utility model in conjunction with the specific content of the technical solution.

[0034] Reference Figures 1 to 3 The following are several embodiments of the nasal drug delivery tube of this utility model.

[0035] like Figures 1 to 3As shown, the nasal administration tube 100 of this embodiment includes a tube body 200, with an internal ventilation chamber 300. The tube body 200 extends in a straight line, with its two ends being a first ventilation port 210 and a second ventilation port 220, respectively. The first ventilation port 210 and the second ventilation port 220 are respectively connected to the ventilation chamber 300. Therefore, when the nasal administration tube 100 is inserted into the patient's nasal cavity, the patient can use nasal ventilation through the connected first ventilation port 210, ventilation chamber 300, and second ventilation port 220, avoiding the need for mouth breathing when administering medication via the nose. Mouth breathing can cause harm such as dry mouth, changes in facial appearance, oral diseases, sleep disturbances, and snoring.

[0036] It is understood that the nasal administration tube 100 also includes a drug capsule 400, which is sleeved outside the tube body 200. Both ends of the drug capsule 400 in a straight direction are connected to the outer wall of the tube body 200, so that the outer wall of the tube body 200 and the drug capsule 400 surround each other to form an administration cavity 410. Figure 2 As shown. A cotton pad 500 is provided inside the drug delivery chamber 410. The cotton pad 500 can be soaked with liquid drug to form a medicated cotton, such as... Figure 2 As shown. The drug capsule 400 is provided with multiple drug delivery holes 420, which are connected to the drug delivery cavity 410, as shown. Figures 1 to 3 As shown. Therefore, when the nasal administration tube 100 is inserted into the patient's nasal cavity, the cotton pad 500 soaked in the drug continuously administers the drug into the nasal cavity through multiple administration holes 420, so that the drug can continue to take effect.

[0037] With this setup, when administering medication through the nasal cannula 100, it needs to be inserted into the patient's nasal cavity first. The patient then ventilates through the first airway 210, the airway 300, and the second airway 220, and the medication is continuously administered through multiple administration holes 420, thus ensuring the sustained effect of the medication.

[0038] Understandably, the nasal administration tube 100 is inserted into the patient's inferior nasal cavity. Specifically, one end of the tube 200 is inserted into the patient's inferior nasal cavity from the outside in, so that the entire drug capsule 400 outside the tube 200 is inserted into the patient's inferior nasal cavity. The other end of the tube 200 is located outside the nasal cavity, making it easy to remove the nasal administration tube 100 after the nasal administration is completed.

[0039] In some embodiments, the tube body 200 has the same shape and size at opposite ends, that is, the end of the tube body 200 with the first air port 210 and the end with the second air port 220 have the same shape and size, because either end of the nasal administration tube 100 can be inserted into the patient's nasal cavity.

[0040] In this embodiment, the first airway 210 and the second airway 220 are set separately, so that one end of the tube 200 with the second airway 220 is inserted into the patient's inferior nasal meatus, and the other end of the tube 200 with the first airway 210 is located outside the patient's nasal cavity.

[0041] It is understandable that the end of the tube 200 with the first vent 210 is connected to the injection port 600, such as... Figures 1 to 3 As shown, the injection port 600 and the tube body 200 are fixed relative to each other. The injection port 600 is connected to the drug delivery chamber 410. In use, liquid drugs are drawn up with a syringe, the syringe is inserted into the injection port 600 and the drugs are pushed in. The cotton pad 500 in the drug delivery chamber 410 absorbs the pushed-in drugs, thus becoming medicated cotton.

[0042] Understandably, the injection port 600 and the tube body 200 are set at an angle to facilitate quick differentiation between the injection port 600 and the first vent port 210, preventing the syringe from injecting medication into the first vent port 210. Figures 1 to 3 As shown.

[0043] Understandably, the first vent 210 is funnel-shaped, such as... Figures 1 to 3 As shown, the first nasal vent 210, shaped like a trumpet, is positioned against the patient's nostril to prevent the entire nasal administration tube 100 from being inserted into the patient's inferior nasal meatus, thus avoiding the need to use tweezers or other tools to remove it after nasal treatment.

[0044] Understandably, the second vent 220 is shaped like an eagle's beak, such as... Figures 1 to 3 As shown. Specifically, the second airway 220 decreases in size along the direction away from the first airway 210, so that when the end of the tube 200 with the second airway 220 is inserted into the nasal cavity, the smaller end of the second airway 220 is inserted into the patient's nasal cavity first, and then slowly transitions to the larger end of the second airway 220 and the tube 200, so that the patient can adapt to the nasal administration tube 100 inserted into the inferior nasal meatus.

[0045] It is understandable that the outer wall surface of the tube 200 is provided with a scale 700, and the scale 700 is set along the long end of the tube 200, such as... Figure 1 and Figure 3 As shown. When inserting the nasal administration tube 100, the insertion depth can be adjusted according to the patient's age. The insertion depth of the nasal administration tube 100 can be precisely controlled by the scale 700 on the outer wall of the tube body 200.

[0046] It is understandable that the tube 200 has a cylindrical structure and the outer wall surface of the tube 200 is a circular surface.

[0047] In some embodiments, the sac 400 is annular and connected to the outer circumferential surface of the tube body 200, such as Figure 1As shown. Therefore, viewed in a vertical cross-section along the long end of the tube 200, the drug capsule 400 and the tube 200 form an annular drug delivery cavity 410, as shown. Figure 2 As shown. When using the nasal administration tube 100 for nasal drug administration, the sac 400 needs to be fully inserted into the patient's inferior nasal meatus. The scale 700 is set between the sac 400 and the first airway 210 to facilitate adjustment of the insertion depth of the tube 200 after the sac 400 is fully inserted into the inferior nasal meatus.

[0048] In other embodiments, the sac 400 has a C-shaped structure and is connected to the outer circumferential surface of the tube 200, such as... Figure 3 As shown. Therefore, viewed in a vertical cross-section along the long end of the tube 200, the sac 400 and the tube 200 form a C-shaped drug delivery cavity 410. The graduation 700 is laid along the long end of the tube 200 and located between the two ends of the C-shaped sac 400, facilitating overall control of the insertion depth of the nasal drug delivery tube 100.

[0049] Understandably, since the first airway 210, the second airway 220, and the airway 300 are connected, when the nasal administration tube 100 is inserted into the patient's inferior nasal meatus, the fiberoptic bronchoscope can pass through the first airway 210, the airway 300, and the second airway 220, allowing observation of the patient's nasal mucosa from the second airway 220. The tube body 200 can prevent the lens of the fiberoptic bronchoscope from being contaminated by the nasal cavity, resulting in better observation.

[0050] Understandably, the inner diameter of the ventilation chamber 300 is larger than the diameter of the bronchoscope to ensure that the bronchoscope can be inserted into the ventilation chamber 300.

[0051] In this embodiment, the nasal administration tube 100 is a disposable component, ensuring the patient's hygiene and health safety and avoiding bacterial residue due to improper cleaning or disinfection.

[0052] Understandably, the tube 200 is a flexible plastic tube, which allows it to bend freely during insertion, making it easier to insert into the patient's inferior nasal cavity.

[0053] In some embodiments, the sac 400 is a plastic tube. The tube-shaped sac 400 can be bent by the tube-shaped body 200 to facilitate insertion of the nasal administration tube 100. The administration cavity 410 formed by the tube-shaped sac 400 is of a fixed size, ensuring that the cotton pad 500 can be stably placed in the administration cavity 410, preventing the cotton pad 500 from accumulating at one end of the administration cavity 410 due to external forces, thus affecting the drug administration effect.

[0054] In other embodiments, the sac 400 is a thin film made of plastic. The thin film sac 400 can also be bent along the tubular tube 200 for easy insertion. The thin film sac 400 fits into the moistened cotton wool, allowing the medication in the cotton wool to be better delivered into the nasal cavity through the administration port 420.

[0055] In this embodiment, the diameter of the administration hole 420 is 0.25 mm, and the distance between two adjacent administration holes 420 is 2 mm.

[0056] Understandably, the drug capsule 400 has multiple rows of drug delivery holes 420, and each row of drug delivery holes 420 has multiple drug delivery holes 420 spaced along the long end of the tube 200. Each row of drug delivery holes 420 is laid along the arc direction of the drug capsule 400.

[0057] In some embodiments, each row of drug delivery holes 420 is staggered along the arc direction of the drug capsule 400, so that the spacing between each adjacent drug delivery hole 420 is the same.

[0058] In this embodiment, each row of drug delivery holes 420 is laid out at intervals perpendicular to the long end of the tube body 200, so that adjacent drug delivery holes 420 form a rectangular array, such as... Figures 1 to 3 As shown. The distance between two adjacent administration holes 420 along the long end of the tube body 200 is 2 mm, and the distance between two adjacent administration holes 420 along the direction perpendicular to the long end of the tube body 200 is 2 mm.

[0059] In this embodiment, the outer diameter of the tube 200 is 6.8 mm to ensure that the bronchoscope can be inserted into the ventilation cavity 300.

[0060] In this embodiment, the tube body 200 is 12 cm long, the sac 400 is 9 cm long, the distance between the sac 400 and the first vent 210 is 2 cm, and the distance between the sac 400 and the second vent 220 is 1 cm.

[0061] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention. All such equivalent modifications or substitutions are included within the scope defined by the claims of this application.

Claims

1. A nasal administration tube, characterized in that The device comprises a tube and a medicine bag. The tube has an air passage inside. The tube has a first air passage and a second air passage. The medicine bag is sleeved on the tube. The outer wall of the tube and the medicine bag are connected to form a medicine cavity. A cotton piece is arranged in the medicine cavity. The medicine bag has a plurality of medicine holes.

2. The nasally-administered tube of claim 1, wherein, The tube with the second air passage is inserted into the lower nasal passage of the patient. The tube with the first air passage is located outside the nasal cavity of the patient.

3. The nasally-administrable tube according to claim 2, wherein The tube with the first air passage is connected with a medicine injection port. The medicine injection port is communicated with the medicine cavity.

4. The nasally-administrable tube according to claim 2, wherein The second air passage is in the shape of an eagle beak.

5. The nasally-administrable tube of claim 1, wherein The outer wall of the tube is provided with a scale. The scale is arranged along the long end of the tube.

6. The nasally-administered tube of claim 5, wherein, The medicine bag is in the shape of a ring. The medicine cavity is in the shape of a ring. The scale is arranged between the medicine bag and the first air passage.

7. The nasally-administrable tube of claim 5, wherein The medicine bag is in the shape of a C. The medicine cavity is in the shape of a C. The scale is arranged between the two ends of the C-shaped medicine bag.

8. The nasally-administered tube of claim 2, wherein, A fiber bronchoscope for observing the nasal mucosa passes through the first air passage and extends out of the second air passage through the air passage.

9. The nasally-administered tube of claim 1, wherein, The medicine bag is a plastic soft tube or film.

10. The nasally-administered tube of claim 1, wherein, The diameter of the medicine hole is 0.25 mm. The distance between two adjacent medicine holes is 2 mm. The outer diameter of the tube is 6.8 mm. The length of the tube is 12 cm. The length of the medicine bag is 9 cm.

Images